Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Ibrutinib-Associated Adverse Events

June 30th 2015

Ibrutinib Monotherapy and Combinations in CLL

June 30th 2015

Preventing Infusion Reactions With CD20 Antibodies in CLL

June 30th 2015

Role of B-Cell Receptor Signaling Inhibitors in CLL

June 30th 2015

Changing Treatment Landscape in CLL

June 30th 2015

Future Immunotherapies for Hematologic Malignancies

June 24th 2015

PD-1 Inhibition in Hodgkin's Lymphoma

June 24th 2015

Treatment Advancements in Lymphoma

June 24th 2015

Daratumumab, Vaccines in Multiple Myeloma

June 24th 2015

Elotuzumab in Relapsed/Refractory Multiple Myeloma

June 24th 2015

Measuring Response to Novel Therapies in ALL

June 24th 2015

Blinatumomab in Philadelphia Chromosome-Negative ALL

June 24th 2015

Rituximab, Obinutuzumab, and Ofatumumab in CLL

June 24th 2015

Immunotherapy-Related Adverse Events

June 24th 2015

Responses With Immunotherapy Versus Chemotherapy

June 24th 2015

Immunotherapy in Hematologic Malignancies

June 24th 2015

Expanded Idelalisib Indication in CLL on Horizon After Positive Phase III Combo Trial With Ofatumumab

June 24th 2015

OncLive spoke with Jeffrey Jones, MD, MPH, to better understand the Study 119 results, as well as the role idelalisib and other novel targeted agents will play in CLL going forward.

HELIOS Ibrutinib Data 'Practice Changing' for CLL, Says Chanan-Khan

June 23rd 2015

Lead author Asher A. Chanan-Khan, MD, discusses the HELIOS trial, in which adding ibrutinib to bendamustine and rituximab lowered the risk of disease progression by 80% in patients with CLL.

Dr. Chanan-Khan Discusses Ibrutinib and BR in CLL

June 23rd 2015

Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Cancer Center, Mayo Clinic, discusses ibrutinib (Imbruvica) combined with rituximab and bendamustine (BR) as treatment of chronic lymphocytic leukemia (CLL) from a mechanism of action point of view.

Martin Barrett on Intravenous Versus Subcutaneous Rituximab

June 20th 2015

Martin Barrett, PhD, Clinical Scientist at Hoffmann-La Roche, discusses a study which compared intravenous (IV) rituximab to subcutaneous rituximab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).